HONG KONG, April 27, 2026 /PRNewswire/ -- J&T Global Express Limited ("J&T Express" or "J&T" or "the Company", stock code: 01519), a global logistics service provider, today released its 2025 Environmental, Social and Governance (ESG) Report. The report comprehensively presents the Company's latest practices and achievements in intelligent operations, energy management, employee rights protection, talent development, business ethics management, and social welfare, demonstrating its firm commitment to integrating sustainable development concepts into its global logistics network and continuously promoting high-quality development.

Deepening Green Operations and Continuously Promoting Energy Conservation and Carbon Reduction

Over the past year, J&T Express has continued to advance smart logistics and energy transition, utilizing technologies such as AI and big data throughout the entire process of pickup, sorting, line-haul transportation, and delivery to optimize transportation routes, improve transit and sorting efficiency, and enhance last-mile delivery capabilities. In terms of transit, by the end of 2025, J&T Express had put into operation a total of 14 self-built core logistics parks globally, with a total gross floor area of 1.05 million square meters. In addition, the Company has invested heavily in energy-saving logistics equipment, deploying over 150,000 permanent magnet synchronous motorized rollers and more than 400 energy-saving conveyor belts. In terms of last-mile transportation, J&T Express is accelerating the construction of an autonomous vehicle delivery network, with the number of autonomous vehicles put into operation exceeding 1,000 by the end of 2025, leveraging intelligent algorithms to achieve optimal route planning and improve last-mile delivery efficiency. In terms of green packaging, the cumulative deployment of reusable transit bags globally reached approximately 38.27 million, with cumulative usage reaching approximately 3.33 billion times.

In terms of low-carbon transportation, J&T Express has continuously promoted the use of clean and electric transportation vehicles. In China, the Company had been investing in new LNG tractors in 2025, bringing the total to 1,697, accounting for 30% of the total number of self-owned tractors, with the greenhouse gas emission intensity of self-owned line-haul vehicles decreasing by 6% compared to 2024. The Philippines took the lead in achieving 100% use of B5 biodiesel for vehicle transportation; Singapore introduced electric trucks, accounting for 6% of its total truck fleet. At the same time, the Company promoted the coordinated development of green transportation methods such as railway and maritime transport, further optimizing the transportation structure and improving efficiency.

Strengthening Employee Care and Safeguarding Rights and Growth

J&T Express continues to create an open, inclusive, and equal-opportunity work environment, improving its employee care system around career growth, health management, and employee welfare and care. In China, the 2025 J&T Express Co., Ltd. (Entire Network) Platform Algorithm and Labor Rules Agreement was implemented in Shanghai last July, becoming the first network-wide algorithm negotiation agreement in China's express delivery industry. It covers over 290,000 workers in J&T Express's self-operated and franchise outlets across provinces and regions in Chinese Mainland. Focusing on three major issues: salary protection, career development, and algorithm transparency, it further improves the rights protection mechanism for workers in new forms of employment.

In terms of talent development, J&T Express systematically advanced the construction of a multi-level talent training system around four strategic directions: "building channels, supplying talent, strengthening overseas presence, and solidifying foundations." In 2025, the total number of courses on the digital training and knowledge management platform for global employees increased by 60% year-over-year (YoY), and total training hours increased by 2.8 times YoY. In addition, during the reporting period, the Company organized and participated in various safety training sessions globally over 27,000 times, covering over 1.4 million participants, continuously consolidating its safety culture and employee protection foundation.

Fulfilling Social Responsibilities and Supporting Local Community Development

J&T Express continued to carry out social welfare actions in areas such as rural revitalization, educational public welfare, and post-disaster assistance. In Chongqing, China, the Company introduced drones for the first time to collect and transport navel oranges in mountainous areas, with a single drone providing a daily transport capacity of up to 10,000 kilograms, effectively reducing labor costs for fruit farmers. In Thailand, the Company partnered with the Department of Agricultural Extension to launch fresh fruit logistics services, facilitating the efficient circulation of agricultural products.

In terms of emergency disaster relief, the Company's teams in various countries continued to participate in disaster assistance efforts. Following the fire in Tai Po, Hong Kong, J&T Express swiftly initiated a special donation of HK$10 million and delivered 300 sets of daily necessities to temporary shelters. After the floods in Indonesia, the Company's Indonesian headquarters chartered flights to transport 13 tons of supplies to severely affected areas, supporting the affected population in restoring their livelihoods.

Improving Business Ethics and Building a Solid Global Compliance Bottom Line

In terms of business ethics and compliance management, J&T Express continued to improve its global governance system, which is coordinated by the Group headquarters and executed locally by subsidiaries, covering multiple dimensions such as anti-corruption, fair competition, and supply chain compliance. During the reporting period, the Company conducted special training on anti-money laundering, counter-terrorist financing, and anti-corruption for directors and senior management, achieving a 100% coverage rate. It also carried out integrity education and training, covering over 89,000 participants cumulatively, and extended compliance requirements to the supply chain system, further solidifying the foundation for global operations.

Dylan Tey, Chief Financial Officer of J&T Express, stated: "Within J&T's rapidly developing global logistics network, ESG has evolved from a concept into concrete operational capabilities. Over the past year, we have proactively explored green transportation transformation and the governance of new forms of employment, including advancing diversified low-carbon transportation solutions and establishing one of the industry's first algorithm negotiation mechanisms. These relevant practices have received multiple industry recognitions. Looking ahead, J&T will continue to leverage technology to empower operations and let responsibility drive growth, continuously improving our ESG governance system and the quality of information disclosure to create long-term value for key stakeholders including global customers, employees, and communities."

• Total Revenue Reached RMB 12.44 Billion; Revenue from Continuing Operations Up 39.4% YoY
• Adjusted Non-IFRS Net Profit Up 71.7% YoY to RMB 4.60 Billion
• Backlog for Continuing Operations Up 23.6% YoY to RMB 59.77 Billion

SHANGHAI, April 27, 2026 /PRNewswire/ -- WuXi AppTec (stock code: 603259.SH / 2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), today announced financial results for the first quarter ending March 31, 2026 ("Reporting Period"): 

• Total revenue reached RMB 12.44 billion, up 28.8% YoY; revenue from Continuing Operations up 39.4% YoY.
• Adjusted non-IFRS gross profit margin up 8.5pts YoY to 50.4%.
• Adjusted non-IFRS net profit up 71.7% YoY to RMB 4.60 billion; adjusted non-IFRS net profit margin up 9.2pts YoY to 37.0%; adjusted non-IFRS diluted EPS^[1] up 67.0% YoY to RMB 1.57.
• Net profit^[2] up 26.7% YoY to RMB 4.65 billion; diluted EPS up 23.4% YoY to RMB 1.58.
• Backlog for Continuing Operations reached RMB 59.77 billion as of March 31,2026, up 23.6% YoY, as we continue to focus on our core CRDMO strategy and further enhance business visibility. 
• Adjusted operating cash flow^[3] up 21.7% YoY to RMB 3.69 billion, driven by sustained business growth, enhanced operational efficiency and financial management.
• Sustained and steady business growth driven by our unique, fully integrated CRDMO platform. Guided by "follow the molecule" and "win the molecule" strategies, WuXi Chemistry's small molecule CRDMO pipeline continues to efficiently convert and capture high-quality molecules, delivering sustained business growth. In the first quarter of 2026, we added 328 new molecules to the small molecule Development and Manufacturing (D&M) pipeline. As of March 31, 2026, our small molecule D&M pipeline reached 3,550 molecules, representing an increase of 9 projects in phase III and commercial stages in the first quarter of 2026.
• The Company reaffirms its full-year guidance with strong confidence. We are closely monitoring market dynamics and business development, and will raise guidance when appropriate.

Management Comment 

Dr. Ge Li, Chairman and CEO of WuXi AppTec, said, "In the first quarter, our business segments delivered broad-based momentum, with strong growth in both revenue and profit. Our backlog of RMB 59.8 billion for Continuing Operations reflects the strength of our unique CRDMO business model, efficiently enabling the growing needs of our customers."

"Building on this solid performance and sustained efficient execution, we are fully confident in achieving our 2026 full-year guidance. We are accelerating proactive capacity planning and global capability building, continuously enhancing operational and management resilience, and delivering even greater value for customers and shareholders."

"WuXi AppTec remains committed to our core value of 'doing the right thing and doing it right,' enabling our global partners and realizing our vision that 'every drug can be made and every disease can be treated.'"

Business Performance by Segment

• WuXi Chemistry: Continuous Pipeline Expansion and Steady Late-stage Progression, While Accelerating Proactive Capacity Planning
  • Driven by steady pipeline progression to late stages, and the sequential ramp-up of new capacity throughout last year, Q1 revenue of WuXi Chemistry reached RMB 10.62 billion, up 43.7% YoY.
  • With continued optimization of production processes and improvements in capacity efficiency driven by the growth of late-stage clinical and commercial projects, Q1 adjusted non-IFRS gross profit margin of WuXi Chemistry steadily improved 5.4pts YoY to 52.8%.
  • We are accelerating proactive capacity planning. We plan to initiate the new Changzhou site ahead of schedule to better meet growing customer demand.
  • Small molecule drug discovery service ("R") continues to generate downstream opportunities. In the past 12 months, we successfully synthesized and delivered more than 420,000 new compounds to global customers. Meanwhile, 83 molecules were converted from R to D phase. Guided by our "follow-the-customer" and "follow-the-molecule" strategies, we have built trusted partnerships that underpin the sustainable growth of our CRDMO business.
  • Small molecule D&M service maintains strong momentum.

i. The small molecule CDMO pipeline continued to expand, adding 328 new molecules in the first quarter of 2026. As of March 31, 2026, our pipeline reached 3,550 molecules, including 89 commercial projects, 94 in phase III, 386 in phase II and 2,981 in phase I and pre-clinical stages. Notably, commercial and phase III projects increased by 9 during the first quarter.
ii. With our business model continuously attracting high-quality molecules, and the pipeline steadily advancing to late stages, aligned with proactive capacity planning and strong execution, Q1 revenue of small molecule D&M rose 80.1% YoY to RMB 6.93 billion.

• • TIDES business (oligo and peptides) sustains rapid growth.

i. TIDES Q1 revenue up 6.1% YoY to 2.38 billion, with full-year revenue expected to grow about 40% YoY.
ii. TIDES D&M customers grew 28% YoY, and molecules grew 59% YoY.

• WuXi Testing^[4]: Strengthening Differentiated Capabilities and Operational Management; Drug Safety Evaluation Services Maintained Leading Position
  • WuXi Testing Q1 revenue increased 27.4% YoY to RMB 1.13 billion. Notably, revenue from drug safety evaluation services grew 34.8% YoY, maintaining an industry-leading position in the Asia-Pacific region.
  • Driven by differentiated capabilities and enhanced operational management, WuXi Testing gross profit margin continued to improve sequentially each quarter, with Q1 adjusted non-IFRS gross profit margin up 10.8pts YoY to 35.5%.
  • The Company is committed to actively enabling customers in global licensing deals. New modality business continued its strong momentum, contributing more than 30% of WuXi Testing Q1 revenue, while maintaining its leading position in areas including nucleic acids, conjugates, multispecific antibodies and peptides.
  • The Company continued to drive excellence across R&D and service capabilities, with DMPK steadily advancing new capacity in Qidong and Shanghai to efficiently respond to growing and diversified customer demand.

• WuXi Biology: Continues to Follow the Science & Generate Downstream Opportunities; In Vivo & In Vitro Synergies and New Modalities Drove Growth  
  • WuXi Biology builds differentiated drug discovery capabilities in emerging therapeutic areas. It actively expands global business and efficiently generates downstream opportunities for the CRDMO model by continuously contributing more than 20% of the Company's new customers.
  • We efficiently enable our global customers through integrated in vitro & in vivo drug discovery capabilities, cross-regional collaboration and end-to-end solutions in emerging areas. Q1 revenue of WuXi Biology reached RMB 0.67 billion, up 10.1% YoY.
  • With continuous business integration and enhanced operational efficiency, WuXi Biology Q1 adjusted non-IFRS gross profit margin increased 0.4pts YoY to 36.7%. WuXi Biology closely follows the market and maintains a dynamic pricing strategy, maximizing its value in generating downstream opportunities.
  • We achieved rapid revenue growth driven by accelerated progress in integrated in vitro screening and enhanced in vivo pharmacology capabilities. Non-oncology business maintained a competitive edge, serving as a key growth contributor.
  • New modality business continued to drive growth, contributing more than 30% of WuXi Biology Q1 revenue, supported by rapid new customer expansion in areas including nucleic acids, antibody conjugates and peptides.

This release provides a summary of the results and does not intend to provide a complete statement relating to the Company, its securities, or any relevant matters herein that a recipient may need in order to evaluate the Company. For additional information, please refer to the WuXi AppTec 2026 First Quarterly Results Presentation and 2026 First Quarterly Report disclosed on the Company's official website, as well as the Company's disclosure documents and information on the websites of Shanghai Stock Exchange and The Stock Exchange of Hong Kong Limited. Investors are advised to exercise caution and be aware of the investment risks in trading Company shares.

Net profit attributable to the owners of the Company ("Net Profit") is prepared in accordance with China Accounting Standards for Business Enterprises ("CAS"), in currency of RMB. All other financial information disclosed in this press release is prepared in accordance with the International Financial Reporting Standards Accounting Standards ("IFRS"), in currency of RMB.

The 2026 First Quarterly Report of the Company has not been audited.

About WuXi AppTec

WuXi AppTec is a trusted partner and contributor to the pharmaceutical and life sciences industries, providing R&D and manufacturing services that help advance healthcare innovation. With operations across Asia, Europe, and North America, we offer integrated, end-to-end services through our unique CRDMO (Contract Research, Development, and Manufacturing Organization) platform. We are privileged to work alongside partners across 30+ countries, supporting their efforts to bring breakthrough treatments to patients. Guided by our vision that every drug can be made and every disease can be treated, we are committed to advancing breakthroughs for patients—one collaboration at a time. Learn more at https://www.wuxiapptec.com.

Forward-Looking Statements

This press release may contain certain statements that are or may be forward looking, which can be recognized by the use of words such as "expects", "plans", "will", "estimates", "projects", "intends", or words of similar meaning. Such forward-looking statements are not historical facts, but instead are predictions about future events based on our beliefs, development strategy, business plan as well as assumptions made by and information currently available to our management. Although we believe that our predictions are reasonable, future events are inherently uncertain and our forward-looking statements may turn out to be incorrect. Our forward-looking statements are subject to risks relating to, among other things, our ability to meet timelines for the expansion of our service offerings or to reach the scale of our production capacity expansion plans, our ability to protect our clients' intellectual property, competition, unforeseeable change of international policy, the impact of emergencies and other force majeure. Our forward-looking statements do not constitute any profit forecast by our management nor an undertaking by WuXi AppTec Co., Ltd. ("WuXi AppTec" or the "Company") to our investors. ACCORDINGLY, YOU ARE STRONGLY CAUTIONED THAT RELIANCE ON ANY FORWARD-LOOKING STATEMENTS INVOLVES KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement or information in this press release to reflect future events or circumstances, except as required under applicable law.

Continuing Operations and Discontinued Operations

In accordance with IFRS, the Company has classified operations with signed equity sale agreements, completed sales, or those being discontinued during the reporting period or comparative periods as discontinued operations ("Discontinued Operations"). Comparative disclosures have been adjusted accordingly. The remaining operations of the Company will continue to be reported as continuing operations ("Continuing Operations").

Use of Adjusted Non-IFRS Financial Measures

To supplement the Company's IFRS consolidated financial statements, we also provide adjusted non-IFRS gross profit, adjusted non-IFRS net profit attributable to the owners of the Company ("Adjusted Non-IFRS Net Profit), adjusted non-IFRS diluted earnings per share ("Adjusted Non-IFRS Diluted EPS") and adjusted operating cash flow. These measures are not required by, or presented in accordance with IFRS.

We believe that the adjusted non-IFRS financial measures used in this presentation are useful for understanding and assessing our core business performance and operating trends, and we believe that management and investors may benefit from referring to these measures in assessing our financial performance by eliminating the impact of certain unusual, non-recurring, non-cash and non-operating items that we do not consider indicative of the performance of our core business. The management of the Company believes such adjusted non-IFRS financial measures is widely accepted and adopted in the industry the Company operates. However, the presentation of these adjusted non-IFRS financial measures is not intended to be considered in isolation, or as a substitute for the financial information prepared and presented in accordance with IFRS. You should not view adjusted results on a stand-alone basis or as a substitute for results under IFRS, or as being comparable to results reported or forecasted by other companies.

XPENG-W (09868.HK) is set to disclose a more advanced, automotive-grade, anthropomorphic robot in 3Q26, Chairman and CEO He Xiaopeng revealed at the 2026 Beijing Auto Show. The carmaker is also aiming to mass-produce robots in China by the end of 2026 and to kick off deliveries in more countries next year.

Regarding flying cars, He also disclosed that XPENG-W is developing a second-generation flying car, which is intended to suit not only China but also overseas markets like Europe and the US.

When asked about comparisons between XPENG-W's VLA and Tesla (TSLA.US)'s FSD, He said that both Tesla's FSD in the US and the advanced driver assistance systems of XPENG-W, NIO-SW (09866.HK), and Huawei in China are excellent.
~



AAStocks Financial News
Web Site: www.aastocks.com

美國馬里蘭州羅克維爾市和中國蘇州2026年4月27日 /美通社/ -- 致力於在腫瘤等領域開發創新藥物的領先的生物醫藥企業——亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）今日宣佈，公司自主研發的1類新藥、中國首個上市的國產原創Bcl-2抑制劑利生妥^®（利沙托克拉），獲納入最新發佈的2026年中國臨床腫瘤學會（CSCO）系列指南。在2026 版《CSCO 淋巴瘤診療指南》與《CSCO 惡性血液病診療指南》中，利沙托克拉憑借在多項臨床研究中的卓越表現，正式確立了在慢性淋巴細胞白血病/小淋巴細胞淋巴癌（CLL/SLL）、急性髓系白血病（AML）和骨髓增生異常綜合征（MDS）領域的權威推薦地位 。

一、 CLL/SLL 領域：實現從單藥到聯合的全覆蓋

在2026版《CSCO 淋巴瘤診療指南》中，利沙托克拉形成了階梯式的精準化佈局：

• I 級推薦（單藥/復發難治）：基於APG2575CC201研究在高危、BTKi經治人群中的顯著獲益（ORR達62.5%），利沙托克拉單藥獲I級推薦（高證據級別），成為復發難治性CLL/SLL患者的標準治療方案 。
• II 級推薦（聯合方案/復發難治）：利沙托克拉聯合利妥昔單抗在復發/難治性CLL/SLL患者獲 II 級推薦 。
• III 級推薦（前沿探索）：針對BTK抑制劑和維奈克拉治療後復發/難治CLL/SLL 患者，利沙托克拉聯合阿可替尼展現出巨大治療潛力，ORR達96.9%，獲III級推薦，是此類推薦中唯一列入的Bcl-2抑制劑治療方案。

二、 AML 領域：精準分層下的核心一線與耐藥替代方案

在2026版《CSCO 惡性血液病診療指南》中，利沙托克拉通過機制類別的更新，進一步鞏固了其在髓系腫瘤中的基石地位：

• 一線核心推薦： 針對老年/不適合強化化療（Older/Unfit）患者，指南將「BCL-2 抑制劑（包含利沙托克拉）」聯合去甲基化藥物（AZA/DAC）或低劑量阿糖胞甘（LDAC）列為一線方案的核心推薦 。
• 耐藥患者突破： 特別是針對既往有 HMA 暴露的 Unfit 患者，指南新增了「LDAC+ Bcl-2抑制劑」方案。利沙托克拉憑借其獨特的藥代動力學優勢，成為此類經治/耐藥患者的重要替代選擇 。
• 難治/復發挽救：對早期復發患者靶向治療或靶向聯合化療時，指南新增了利沙托克拉同樣可作為Bcl-2抑制劑的可選藥物。

三、 MDS 領域：延續了 Bcl-2抑制劑 聯合 HMA 在較高危MDS中的治療價值

在2026版《CSCO 惡性血液病診療指南》中，對於初治較高危MDS及復發、進展或無反應者推薦了去甲基化藥物HMA聯合Bcl-2抑制劑的治療方案。指南中也提到新型Bcl-2抑制劑利沙托克拉聯合AZA用於新診斷HR-MDS的全球註冊III期臨床試驗（GLORA-4）已獲批開展，目前正在進行中。利沙托克拉作為我國首個原創全新一代 Bcl-2 抑制劑，在較高危MDS患者的治療中同樣具有臨床應用價值。

利沙托克拉是亞盛醫藥自主研發的新型口服Bcl-2選擇性抑制劑，通過選擇性抑制Bcl-2蛋白，恢復癌細胞的正常凋亡過程，從而達到治療腫瘤的目的。2025年7月，該藥物在中國獲批上市，用於既往經過至少包含布魯頓酪氨酸激酶抑制劑（BTKi）在內的一種系統治療的成人CLL/SLL患者。利沙托克拉是中國首個上市的國產原創Bcl-2抑制劑，也是全球第二個上市的Bcl-2抑制劑、全球首個單藥治療BTK抑制劑經治的Bcl-2抑制劑，具有重大臨床價值。

哈爾濱血液病腫瘤研究所所長：「近年來，國內生物製藥公司在創新藥研發上取得了顯著突破，利沙托克拉作為中國首個原創Bcl-2抑制劑備受關注，在CLL/SLL中的臨床療效得到指南的認可並在臨床實踐中獲得檢驗。除CLL/SLL外，利沙托克拉在老年/不適合強化化療（Older/unfit）的急性髓系白血病（AML）患者中，與去甲基化藥物（如地西他濱、阿扎胞甘）或化療方案聯合應用，以及利沙托克拉聯合AZA治療較高危MDS患者，都顯示出良好療效。隨著研究探索進展，利沙托克拉在血液腫瘤中的治療價值不斷被明確，在2026版《CSCO淋巴瘤指南》與《CSCO惡性血液病指南》更新中進一步強化了Bcl-2抑制劑在血液腫瘤中的臨床地位。我們始終秉承「一切為了創新，一切為了患者」的初心，展望未來，隨著更多適應症的拓展與申報推進，利沙托克拉有望覆蓋包括AML、MDS在內的更廣泛人群，持續釋放臨床價值。為了讓前沿創新真正惠及大眾，未來應進一步提升可及性，期盼利沙托克拉能盡早納入國家醫保體系，使更多有迫切治療需求的患者能切實從中獲益，提升血液腫瘤整體治療水平與公平性。相信隨著對利沙托克拉的不斷探索與深入應用，將為血液腫瘤的治療開創更多可能。」

亞盛醫藥首席醫學官翟一帆博士表示：「CSCO指南是中國臨床醫生進行腫瘤臨床診斷和治療的重要依據，是國內最具有學術影響力的診療指南之一。作為中國首個獲批上市的國產原創Bcl-2抑制劑，此次利沙托克拉在 2026 版CSCO系列指南中的全面落地，充分展現了該產品在多個血液腫瘤領域的卓越臨床價值。這不僅打破了該領域長期依賴進口藥物的局面，更憑借」每日梯度劑量遞增「等更符合中國臨床實際的差異化優勢，重塑了中國血液腫瘤的治療格局，為患者提供了更前沿、更具可及性的創新方案。我們期待利沙托克拉這一重磅創新藥產品在CSCO指南的嚴謹指導下，更好地服務血液腫瘤領域的臨床治療，惠及更廣泛的患者。」

關於亞盛醫藥

亞盛醫藥（納斯達克代碼：AAPG；香港聯交所代碼：6855）是一家綜合性的全球生物醫藥企業，致力於研發、生產和商業化創新藥，以解決腫瘤領域全球患者尚未滿足的臨床需求。公司已建立豐富的創新藥產品管線，包括抑制Bcl-2和 MDM2-p53 等細胞凋亡通路關鍵蛋白的抑制劑、新一代針對癌症治療中出現的激酶突變體的抑制劑以及蛋白降解劑。

公司核心品種耐立克^®是中國首個獲批上市的第三代BCR-ABL抑制劑，已獲批用於治療伴有T315I突變的慢性髓細胞白血病慢性期（CML-CP）和加速期（CML-AP）患者，以及對一代和二代TKI耐藥和/或不耐受的CML-CP成年患者。該藥物所有獲批適應症均已被納入中國國家醫保藥品目錄（NRDL）。目前，亞盛醫藥正在開展耐立克^®三項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲EMA許可的評估耐立克^®治療新診斷費城染色體陽性急性淋巴細胞白血病（Ph+ ALL）患者POLARIS-1研究；獲美國FDA和歐洲EMA許可的評估耐立克^®治療經治CML-CP成年患者的POLARIS-2研究；評估耐立克^®治療SDH-缺陷型GIST患者的POLARIS-3研究。

公司另一重磅品種利生妥^®是一款用於治療多種血液系統惡性腫瘤的新型Bcl-2抑制劑。利生妥^®已獲中國國家藥品監督管理局（NMPA）批准，用於治療既往至少接受過一種包括布魯頓酪氨酸激酶（BTK）抑制劑在內的系統治療的成人慢性淋巴細胞白血病/小淋巴細胞淋巴瘤（CLL/SLL）患者。目前，亞盛醫藥正在開展利生妥^®四項全球註冊III期臨床研究，分別為：獲美國FDA和歐洲MEA許可的評估利生妥^®聯合BTK抑制劑治療既往接受BTK抑制劑治療超過12個月且應答不佳的CLL/SLL患者的GLORA研究；評估利生妥^®一線治療初治CLL/SLL患者的GLORA-2研究；評估利生妥^®一線治療新診斷老年或不耐受的AML患者的GLORA-3研究；以及獲美國FDA和歐洲EMA許可的評估利生妥^®一線治療新診斷中高危MDS患者的GLORA-4研究。

憑借強大的研發能力，亞盛醫藥已在全球範圍內進行知識產權佈局，並與武田、阿斯利康、默沙東、輝瑞、信達等眾多領先的生物製藥公司達成全球合作，同時與丹娜法伯癌症研究院、梅奧醫學中心、美國國家癌症研究所和密西根大學等學術機構建立研發合作關係。如需瞭解更多信息，請訪問 https://ascentage.com/

前瞻性聲明

本新聞稿包含根據美國《1995年私人證券訴訟改革法案》，以及經修訂的《1933年證券法》第27A條和《1934年證券交易法》第21E條所界定的前瞻性陳述。除歷史事實陳述外，本新聞稿中的所有內容均可能構成前瞻性陳述，包括亞盛醫藥對未來事件、經營成果或財務狀況所發表的意見、預期、信念、計劃、目標、假設或預測。

這些前瞻性陳述受到諸多風險和不確定性的影響，具體內容已在亞盛醫藥向美國證券交易委員會（SEC）提交的文件中詳細說明，包括2025年1月21日提交的經修訂的F-1表格註冊說明書和2025年4月16日提交的20-F表格中的「風險因素」和「關於前瞻性聲明的警示聲明」章節、2019年10月16日提交的首次發行上市招股書中的「前瞻性聲明」、「風險因素」章節，以及我們不時向SEC或HKEX提交的其他文件。這些因素可能導致實際業績、運營水平、經營成果或成就與前瞻性陳述中明示或暗示的信息存在重大差異。本前瞻性聲明中的陳述不構成公司管理層的利潤預測。

因此，該等前瞻性陳述不應被視為對未來事件的預測。本新聞稿中的前瞻性陳述僅基於亞盛醫藥當前對未來發展及其潛在影響的預期和判斷，且僅代表截至陳述發表之日的觀點。無論出現新信息、未來事件或其他情況，亞盛醫藥均無義務更新或修訂任何前瞻性陳述。

北京2026年4月26日 /美通社/ -- 耐世特助力頭部新能源車企，實現全球首款 「完全體」 全線控底盤量產乘用車落地，其線控轉向系統由耐世特提供全套配套方案。

該車型搭載的線控轉向系統，為耐世特全球首個實現量產交付的線控轉向項目，標志著線控轉向技術正式從研發驗證階段邁入規模化量產應用。該系統於 2025 年底獲得德國國家認可委員會（DAkkS）頒發的全球首個 ASIL D 級別功能安全認證，是雙方深度協同、聯合開發的技術成果，代表系統在故障診斷、容錯機制、安全監控等維度達到全球頂尖安全標准。該系統核心特性如下：

• 多重冗余設計：雙控制器、雙電源、多重通信鏈路、雙執行路徑，從系統、硬件到軟件實現多層冗余，確保單一故障時備份鏈路毫秒級接管，無轉向功能喪失；
  
  
• 全場景功能安全機制：覆蓋傳感器、控制器、執行器及通信鏈路的多層監控與故障處理策略；
  
  
• 轉向比可調：根據車速和駕駛模式自動調整轉向角度與力度，兼顧操控性與舒適性；
  
  
• 智能手感模擬技術：通過軟件定義路感反饋，提供更靈敏、精準的駕駛體驗，適配多樣駕駛場景；
  
  
• 面向自動駕駛的開放接口：作為高級駕駛輔助及自動駕駛系統的關鍵執行層，提供實時精確的控制能力，助力智能交通系統發展。

線控轉向：電子信號替代機械連接，靈活組合滿足多元需求

線控轉向通過解耦方向盤與車輪之間的機械連接，以電信號和執行器替代傳統結構，正成為下一代智能底盤與自動駕駛平台的關鍵基礎技術。作為擁有120余年工程積澱的運動控制技術公司，耐世特提供多種手感模擬器與輪端執行器的靈活搭配方案，形成「貨架式」產品組合，充分滿足不同車型與駕駛場景的差異化需求。

從轉向到制動：全棧式運動控制能力持續拓展

基於在轉向系統領域的深厚積累，耐世特已將技術能力自然延伸至制動領域。電子機械制動（EMB）產品已完成全系列開發與嚴苛驗證，具備量產條件。EMB與線控轉向（SbW）、後輪轉向（RWS）及MotionIQ™軟件套件，共同構建了耐世特全面、開放的Motion-by-Wire™線控運動控制產品生態。

選擇耐世特，整車廠得到的不僅是線控轉向與線控制動部件，更是一套完整、成熟、可量產且高性價比的線控底盤運動控制解決方案。該方案正助力塑造軟件定義底盤的未來，賦能整車廠實現更快的開發節奏、更低的成本，並最終為終端用戶帶來更安全、更智能、更激動人心的駕駛體驗。

北京車展期間，誠邀您蒞臨中國國際展覽中心（順義館）W1館W1B03耐世特展台，親身體驗線控轉向及Motion-by-Wire™線控運動控制等前沿技術帶來的突破性創新成果。

關於耐世特汽車系統

耐世特汽車系統（HK 1316）作為一家領先的運動控制技術公司，加速實現安全、綠色和振奮人心的移動出行。我們創新的產品和技術組合為底盤的「線控運動控制」（Motion-by-Wire™）提供助力，包括電動助力和液壓助力轉向系統、線控轉向和後輪轉向系統、轉向管柱與中間軸、驅動系統、軟件解決方案以及線控制動，為包括電氣化、軟件/網聯、先進駕駛輔助系統（ADAS）/自動駕駛和共享出行在內的所有大趨勢所面臨的運動控制挑戰提供解決方案，為全球60余家客戶提供服務，包括寶馬、福特、通用、雷諾日產三菱、斯泰蘭蒂斯、豐田、大眾，以及中國的比亞迪、小米、長安、理想、奇瑞、長城、吉利、小鵬等和印度的汽車製造商。www.nexteer.com

訪問耐世特媒體庫

BEIJING, April 26, 2026 /PRNewswire/ -- Nexteer Automotive helped a leading Chinese new energy vehicle (NEV) manufacturer bring the world's first production passenger vehicle with a full drive‑by‑wire chassis to market. The vehicle features Nexteer's steer‑by‑wire (SbW) system as a key enabler.

The SbW featured in this vehicle marks Nexteer's first SbW system in mass production, representing a major step forward for the technology — moving from development and validation to full-scale production. Certified in late 2025, this system achieved the world's first ASIL D functional safety approval from DAkkS (German Accreditation Body) through close collaboration with the OEM. This certification reflects global top-tier performance in fault diagnosis, redundancy, and safety monitoring. Key features include:

• Multi-layered redundancy design: Dual controllers, dual power supplies, multiple communication links, and dual actuation paths — achieving redundancy at system, hardware, and software levels. This ensures that in the event of a single fault, the backup path takes over within milliseconds with no loss of steering function.
• Full‑scenario functional safety mechanism: Multi‑level monitoring and fault handling strategies covering sensors, controllers, actuators, and communication links.
• Variable steering ratio: Automatically adjusts steering angle and effort based on vehicle speed and driving mode, balancing agility and comfort.
• Intuitive road‑feel simulation technology: Software‑defined steering feedback delivers a more responsive and precise driving experience, adaptable to a wide range of driving scenarios.
• Open interface for autonomous driving: As a key actuation layer for ADAS and autonomous driving systems, it provides real‑time, precise control capabilities, supporting the development of intelligent transportation systems.

Steer-by-Wire: Electronic Signals Replace Mechanical Links, Flexible Configurations for Diverse Needs

By decoupling the mechanical link between the hand wheel and the road wheels, steer-by-wire replaces conventional mechanical connections with electronic signals and actuators — and is quickly becoming a foundational technology for next-generation intelligent chassis and autonomous driving platforms. As a motion control technology company with 120 years of engineering heritage, Nexteer offers a flexible, off-the-shelf portfolio of steering feel simulators and road wheel actuators. This modular approach allows us to meet the diverse needs of different vehicle models and driving scenarios efficiently and cost-effectively.

From Steering to Braking: Expanding Full-Stack Motion Control Capabilities

Building on its deep expertise in steering systems, Nexteer has expanded into braking with its Brake-by-Wire solution, the Electro-Mechanical Brake (EMB). EMB has completed full development and rigorous validation and is ready for mass production. Together with SbW, Brake-by-Wire (EMB), Rear-Wheel Steering, and the MotionIQ™ Software Suite make up Nexteer's broader Motion-by-Wire™ portfolio.

With Nexteer, OEMs get more than steer-by-wire and brake-by-wire components: they get a complete, proven, production-ready and cost-effective drive-by-wire chassis motion control solution that's shaping the future of the software-defined chassis and enabling faster development, lower costs and safter, smarter and more exciting driving experiences.

During Auto China 2026, we cordially invite you to visit Nexteer at Booth W1B03, Hall W1, China International Exhibition Center (Shunyi) in Beijing, to experience firsthand the breakthrough innovations of steer-by-wire and Motion-by-Wire™ technologies.

ABOUT NEXTEER AUTOMOTIVE

Nexteer Automotive (HK 1316) is a global leading motion control technology company accelerating mobility to be safe, green and exciting. Our innovative portfolio supports Motion-by-Wire™ chassis control, including electric and hydraulic power steering systems, steer-by-wire and rear-wheel steering systems, steering columns and intermediate shafts, driveline systems, software solutions and brake-by-wire. Celebrating 120 years of automotive innovation in 2026, Nexteer builds on a strong legacy of engineering excellence while continuing to shape the future of mobility. The company solves motion control challenges across all megatrends – including electrification, software/connectivity, ADAS/automated driving and shared mobility – for global and domestic OEMs around the world including BMW, Ford, GM, RNM, Stellantis, Toyota and VW, as well as automakers in India and China including BYD, Xiaomi, ChangAn, Li Auto, Chery, Great Wall, Geely, Xpeng and others. www.nexteer.com  

Links to Nexteer Media Center

BEIJING, April 24, 2026 /PRNewswire/ -- The 19th Beijing International Automotive Exhibition (Auto China 2026) officially opened today, where XPENG made a strong impression with its comprehensive product lineup. The showcase featured several major new models, including the GX, the MONA M03, the next P7, and the X9. In addition to its vehicle portfolio, XPENG showcased its next-generation humanoid robot, IRON, and its flying car "Land Aircraft Carrier". Together, these innovations demonstrate the company's latest advancements and its integrated ecosystem strategy in Physical AI.

XPENG Beijing Autoshow press kit

During the exhibition, around 200 media representatives from Europe, Asia-Pacific, the Americas, the Middle East, and Africa attended XPENG's Physical AI "Immersive" China Tour. Delegates toured XPENG's intelligent manufacturing facilities and ARIDGE's production base, and experienced VLA 2.0 through hands-on test drives. A series of technical seminars provided deeper insight into XPENG's developments in intelligent driving, design, flying vehicles, robotics, powertrain systems, and ultra-fast charging technologies.

XPENG's First VLA 2.0 Intelligent Driving Report Released; Campus and Underground Parking Lot Safari Are Coming Soon

In March 2026, XPENG officially rolled out its VLA 2.0 intelligent driving system. At Auto China 2026, the company released its first VLA 2.0 Intelligent Driving Report, offering a comprehensive analysis of the system's performance across key metrics, including user adoption, engagement, and purchasing influence. The report indicates that VLA 2.0 is playing an increasingly pivotal role in consumer decision-making. Orders for the XPENG Ultra series rose by 118% month-over-month, with advanced intelligent driving capabilities becoming a primary driver of conversions.

Since the launch of in-store VLA 2.0 demonstrations, nearly 100,000 consumers have participated, achieving a 98% satisfaction rate. Notably, the average time from test drive to order placement has decreased by 44.7%, signaling a shift in intelligent driving from a value-added feature to a core purchase consideration. Usage data further demonstrates strong user engagement. During the first week of ownership, 98.52% of users activated intelligent driving features daily. These results suggest that VLA 2.0 effectively addresses long-standing industry challenges related to usability and adoption, delivering a more intuitive and reliable driving experience.

XPENG also announced continued expansion of full-scenario capabilities. New features — Campus and Underground Parking Safari—are scheduled for release soon. These functions are designed to handle complex edge cases, including low-light conditions, adverse weather, absence of navigation data, and unmarked roads, further enhancing end-to-end intelligent mobility.

He Xiaopeng, Chairman and CEO of XPENG, said: "After 12 years, we are entering a new phase. From smart EVs to flying cars, Turing AI chips, large models, humanoid robots, and Robotaxi, we are steadily turning our vision into reality through Physical AI. It is on this integrated technological foundation that we are driving forward the future of mobility. The real value of intelligent driving lies not just in capability, but in delivering greater efficiency and a more relaxing experience."

Advancing Physical AI: A Blueprint for Future Mobility

At the conference, He Xiaopeng introduced the GX, a vehicle designed for the L4 autonomous driving era. Positioned as China's first fully in-house developed, factory-integrated Robotaxi prototype intended for mass production, the GX represents a significant milestone. It is equipped with up to four Turing chips, delivering 3,000 TOPS of computing power, and is powered by the VLA 2.0 system. Built on an architecture purpose-designed for L4 autonomy, the GX sets a new benchmark in intelligent driving capability.

In 2025, XPENG's overseas deliveries surpassed 45,000 units, representing a 96% year-on-year increase, ranking No.1 in overseas pure-electric sales among Chinese NEV startups. Looking ahead, XPENG will continue to deepen its investment in Physical AI technologies while accelerating the commercialization of next-generation products such as the flying car and humanoid robotics. By optimizing user mobility and life experiences through pragmatic technological innovation, XPENG aims to bring efficiency and convenience to a world powered by Physical AI.

About XPENG

Founded in 2014, XPENG is a leading AI-driven mobility company that designs, develops, manufactures, and markets Smart EVs, catering to a growing base of tech-savvy consumers. With the rapid advancement of AI, XPENG aspires to become a global leader in AI mobility, with a mission to drive the Smart EV revolution through cutting-edge technology, shaping the future of mobility. To enhance the customer experience, XPENG develops its full-stack advanced driver-assistance system (ADAS) technology and intelligent in-car operating system in-house, along with core vehicle systems such as the powertrain and electrical/electronic architecture (EEA). Headquartered in Guangzhou, China, XPENG also operates key offices in Beijing, Shanghai, Silicon Valley, and Amsterdam. Its Smart EVs are primarily manufactured at its facilities in Zhaoqing and Guangzhou, Guangdong province. XPENG is listed at the New York Stock Exchange (NYSE: XPEV) and Hong Kong Exchange (HKEX: 9868).

Contacts:

XPENG PR Department
Email: [email protected]
Website: https://www.xpeng.com/

Tesla (TSLA.US) CEO Elon Musk said in a post that production of the Cybercab has commenced, Bloomberg reported.

Unveiled in 2024, the Cybercab is a BEV designed specifically for autonomous taxi (Robotaxi) services. The model is not equipped with a steering wheel or pedals, meaning that mass production will require specific exemptions from US regulators.

Musk stated that the business is unlikely to generate meaningful revenue until at least 2027.
~

AASTOCKS Financial News
Website: www.aastocks.com

GUANGZHOU, China, April 24, 2026 /PRNewswire/ -- MINISO Group Holding Limited (NYSE: MNSO; HKEX: 9896) ("MINISO", "MINISO Group" or the "Company"), a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs, today announced that it will hold an annual general meeting of the Company's shareholders (the "AGM") at 11:00 a.m. Beijing time on June 18, 2026 at Flats B-D, 35/F, Plaza 88, 88 Yeung Uk Road, Tsuen Wan, the New Territories, Hong Kong, for the purposes of considering and, if thought fit, passing each of the proposed resolutions set forth in the notice of the AGM (the "AGM Notice"). The AGM Notice, the ballot, the form of proxy and other documents for the AGM are available on the Company's website at https://ir.miniso.com.

Holders of record of ordinary shares of the Company at the close of business on May 13, 2026, Hong Kong time, are entitled to notice of and to attend and vote at the AGM or any adjournment or postponement thereof. Holders of record of ADSs as of the close of business on May 13, 2026, New York time, who wish to exercise their voting rights for the underlying ordinary shares must give voting instructions directly to The Bank of New York Mellon, the depositary of the ADSs, if ADSs are held on the books and records of The Bank of New York Mellon, or indirectly through a bank, brokerage or other securities intermediary if the ADSs are held by any of them on behalf of holders, as the case may be.

The Company also announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2025 with the United States Securities and Exchange Commission (the "SEC"). The annual report on Form 20-F, which contains the Company's audited consolidated financial statements for the fiscal year ended December 31, 2025, can be accessed on the SEC's website at https://www.sec.gov as well as through the Company's investor relations website at https://ir.miniso.com/.

The Company has also published its Hong Kong annual report today for the fiscal year ended December 31, 2025 pursuant to the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "HKEX"), which can be accessed on the Company's investor relations website at https://ir.miniso.com/ as well as the HKEX's website at https://www.hkexnews.hk.

About MINISO Group

MINISO Group is a global high-growth value retailer offering a variety of trendy lifestyle products featuring distinctive IP designs. Since opening our first store in Chinese mainland in 2013, the Company has successfully built two brands – "MINISO" and "TOP TOY". The Company's flagship brand "MINISO" has grown into a globally recognized retail brand that offers a frequently-refreshed assortment of lifestyle products through an extensive store network worldwide. The Company's products cover diverse consumer needs and consumers are drawn to MINISO for our products' trendiness, creativeness, high quality and affordability. For more information, please visit https://ir.miniso.com/.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the "safe harbor" provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "is/are likely to," "potential," "continue" or other similar expressions. MINISO may also make written or oral forward-looking statements in its periodic reports to the SEC and the HKEx, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about MINISO's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: MINISO's mission, goals and strategies; future business development, financial conditions and results of operations; the expected growth of the retail market and the market of branded variety retail of lifestyle products in China and globally; expectations regarding demand for and market acceptance of MINISO's products; expectations regarding MINISO's relationships with consumers, suppliers, MINISO Retail Partners, local distributors, and other business partners; competition in the industry; proposed use of proceeds; and relevant government policies and regulations relating to MINISO's business and the industry. Further information regarding these and other risks is included in MINISO's filings with the SEC and the HKEx. All information provided in this press release and in the attachments is as of the date of this press release, and MINISO undertakes no obligation to update any forward-looking statement, except as required under applicable law.

Investor Relations Contact:

MINISO Group Holding Limited
Email: [email protected]
Phone: +86 (20) 36228788 Ext.8039

PR Summary
XTEP International, a leading global performance running brand, has opened six new stores in key Malaysian cities, advancing its aggressive Southeast Asia expansion strategy. The launch aligns with surging running demand and government support via Malaysia Aktif and a RM580 million sports budget. XTEP introduced its 360X 3.0 running shoes tailored for local conditions and will host the XTEP 10KM TIME TRIAL. The six stores mark only the start; XTEP plans significant further retail growth to build a full running ecosystem across Malaysia and Southeast Asia.

KUALA LUMPUR, Malaysia, April 24, 2026 /PRNewswire/ -- XTEP International Limited, a leading global performance running brand, today announced the opening of six new stores in key commercial hubs across Malaysia, marking a significant milestone in the brand's strategic expansion across Southeast Asia. The move underscores XTEP's long-term confidence in Malaysia's dynamic running market and confirms plans to grow its retail network well beyond six locations in the country.

Malaysia has emerged as a high-priority market for XTEP, fueled by explosive growth in running participation and strong government support for sports development. The 2025 Kuala Lumpur Standard Chartered Marathon drew a record 42,000 participants, while local race series HSNKL has expanded from 9,000 debut runners to 15,000 today. Supported by the national Malaysia Aktif initiative and a RM580 million allocation for sports development in the 2026 budget, Malaysia offers powerful tailwinds for performance running innovation and community building.

The six new stores are strategically located in Kuala Lumpur, Penang, Johor Bahru, Kuantan, and Shah Alam, serving as core destinations for running enthusiasts. Designed under XTEP's Retail + Community model, these spaces go beyond traditional retail to function as immersive running centers where athletes can test performance footwear, connect with local running clubs, join group training sessions, and engage with product experts.

To address the unique terrain, climate and training needs of Malaysian runners, XTEP has introduced its 360X 3.0 performance running series with the store openings. Engineered for daily training and competitive racing, the collection delivers optimized cushioning, stability and durability, reflecting XTEP's commitment to athlete-driven, localized innovation.

Complementing its retail expansion, XTEP will host the XTEP 10KM TIME TRIAL in Kuala Lumpur. With 1,500 available slots attracting nearly 10,000 registrations, the event highlights strong demand for professional, organized running competition. XTEP will provide participants with premium performance gear to support athletes in pursuing personal bests.

"Malaysia is a cornerstone of XTEP's global strategy and our gateway to Southeast Asia," said a spokesperson for XTEP International. "These six new stores are just the start. We are committed to scaling our retail footprint, building a comprehensive running ecosystem, and becoming the leading performance running brand in the region. XTEP is dedicated to empowering runners through innovative product, professional events and authentic community engagement."

With an expanding retail network, athlete-centric product design and community-focused events, XTEP is positioned to capture significant growth in Southeast Asia's rapidly expanding sports market. As the brand continues its global momentum, Malaysian runners will gain enhanced access to world-class performance running products and experiences.